Interpreting Heidegger in China: Between Modernity and Tradition
Kritike: An Online Journal of Philosophy · 01.02.2026 · 19 (4) · 61-70
DOI: 10.25138/19.4.a7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kritike: An Online Journal of Philosophy, online erschienen am 01.02.2026. Verfasst von Hongjian Wang und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Over the past four decades, Heidegger’s philosophy has exerted a profound influence on Chinese intellectual thought. Within Mainland Chinese academia, two primary approaches to interpreting Heidegger’s work can be identified. The “contemporary” approach, championed by Sun Zhouxing, is rooted in the concerns of modernity, particularly nihilism and the dominance of technology, using these issues as a foundation for proposing a philosophy of the future (未來 哲學). In contrast, the “Chinese” approach, represented by Zhang Xianglong, emphasizes cross-cultural comparisons between Heidegger’s philosophy and Chinese traditional thought, seeking to develop a phenomenology of kinship affection (親親現象學) and a “philosophy of family/home” (家哲學). Both approaches constitute concrete practices of phenomenological interpretation, and through their respective explorations, they demonstrate the universal validity and methodological robustness of Heidegger’s phenomenology, showing its applicability across different cultural and conceptual contexts.
Zitieren
APA
Wang, H., & Wang, Z. (2026). Interpreting Heidegger in China: Between Modernity and Tradition. Kritike: An Online Journal of Philosophy, 19(4), 61-70. https://doi.org/10.25138/19.4.a7
Vancouver
Wang H, Wang Z. Interpreting Heidegger in China: Between Modernity and Tradition. Kritike: An Online Journal of Philosophy. 2026;19(4):61-70. doi:10.25138/19.4.a7
BibTeX
@article{Wang2026,
author = {Wang, Hongjian and Wang, Zhaonong},
title = {Interpreting Heidegger in China: Between Modernity and Tradition},
journal = {Kritike: An Online Journal of Philosophy},
year = {2026},
volume = {19},
number = {4},
pages = {61--70},
doi = {10.25138/19.4.a7}
}
EUVIMED